N/A N=31 Epoetin Alfa in Treating Anemia in Patients Undergoing Chemotherapy for Multiple Myeloma
Anemia · Multiple Myeloma · Plasma Cell Neoplasm
Primary: Change From Baseline in Hemoglobin at Day 28 — 1.3 g/dL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=15 Eribulin Mesylate as Second-Line Therapy for Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer Patients
Adenocarcinoma of the Pancreas · Pancreatic Cancer · Recurrent Pancreatic Cancer
Primary: Objective Response (Complete and Partial) Evaluated Using RECIST Criteria — 0 participants
N/A N=1,170 FAME II - Fractional Flow Reserve (FFR) Guided Percutaneous Coronary Intervention (PCI) Plus Optimal Medical Treatment (OMT) Verses OMT
Coronary Artery Disease
Primary: Major Adverse Cardiac Event Rate (MACE) — 6.7; 32.7; 9.4; 12.2 percentage of subjects with SAEs
Phase 2 N=9 Recombinant Leptin Therapy for Treatment of Nonalcoholic Steatohepatitis (NASH)
Fatty Liver Disease, Nonalcoholic
Primary: Non-alcoholic Steatohepatitis Score as Determined by Liver Histopathology at 12 Months — 5 units on a scale — p=0.015
N/A N=54 Post-market Clinical Follow-up of a Magnetic Bone Conduction Implant (Cochlear Baha Attract System)
Deafness · Hearing Loss · Hearing Loss, Conductive
Primary: Hearing Performance: Threshold Audiometry PTA4: Unaided Versus Baha Attract — -21.0; -20.9; -21.5 dB — p=<0.0001
N/A N=123 Treatment of Stress Urinary Incontinence Via Smartphone
Female Stress Urinary Incontinence
Primary: International Consultation on Incontinence Modular Questionnaire Urinary Incontinence Short Form (ICIQ-UI SF) — 11.1; 11.0; 7.0; 10.2 units on a scale — p=<0.001
N/A N=64,882 Epidemiology of Acute Kidney Injury in England - 1998 to 2013
Acute Kidney Injury
Primary: Secular Trends in the Mortality After Acute Kidney Injury From 1998 to 2013 — 1296; 3763; 19793 participants
Phase 3 N=16 Efficacy of To Be Marketed (TBM) Cholic Acid Capsules Used to Treat Children With Inborn Errors of Bile Acid Synthesis
Inborn Errors of Bile Acid Synthesis
Primary: Serum Transaminases — 31.4; 30.9; 62.7; 65.0 U/L
N/A N=130 "Neutral Head Position" and "Head-lift Position" for Orotracheal Intubation With "Trachway" Intubating Stylet in Adults
Intubation; Difficult
Primary: Intubation Time — 17.5; 21 seconds
Phase 3 N=41 Epoprostenol for Injection in Patients With Pulmonary Arterial Hypertension
Pulmonary Arterial Hypertension
Primary: Treatment-emergent Adverse Events — 41 Number of patients
Phase 2 N=115 Mitoxantrone ± Cetuximab 2nd Line Androgen Independent Prostate Cancer (AIPC)
Androgen-independent Prostate Cancer
Primary: Median Time to Progression (TTP) — 4.9; 6.6 Months
Phase 2 N=195 A Pharmacokinetic Study of MK-1602 in the Treatment of Acute Migraine (MK-1602-007)
Migraine
Primary: Dry Blood Spot (DBS) MK-1602 Concentration at 2 Hours Post-Dose on Migraine Treatment Day — 1.9; 17.0; 43.8; 52.7 nanomolar (nM)
N/A N=98 Corrected VA With Long-Term Follow-Up After AcrySof® Intraocular Lens (IOL) Implantation
Pseudophakia
Primary: Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) at the Long-Term, Post-Implantation Visit — -0.06; -0.09; -0.07; 0.01 logMAR
Phase 2 N=52 SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma
Mucosal Lentiginous Melanoma · Acral Lentiginous Malignant Melanoma
Primary: 2-month Progression-free Survival Rate — .52; .52 proportion of patients
Phase 2 N=36 Phase II Sunitinib Prog Met AIPC
Metastatic Prostate Cancer
Primary: Median Progression-free Survival (PFS) Time at 1-year. — 19.4 weeks